Roche received U.S. FDA Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients (two years and older) who are receiving systemic corticosteroids and require supplemental oxygen. The EUA is based on results from four randomized, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalized patients. The results suggest that Actemra/RoActemra may...